{"id":3893,"date":"2024-06-08T12:35:53","date_gmt":"2024-06-08T05:35:53","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=3893"},"modified":"2024-06-08T12:35:53","modified_gmt":"2024-06-08T05:35:53","slug":"ionetix-produces-first-batch-of-actinium-225","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=3893","title":{"rendered":"IONETIX Produces First Batch of Actinium-225"},"content":{"rendered":"

LANSING, Mich.<\/span>, June 7, 2024<\/span> \/PRNewswire\/ — IONETIX, a leading cyclotron technology innovator, isotope producer, and radiopharmaceutical manufacturer, announced today the successful production of Actinium-225 (“Ac-225”) at its isotope manufacturing facility located in Lansing, Michigan<\/span>.<\/p>\n

This first-of-kind facility is dedicated exclusively to producing alpha-emitting isotopes, including Ac-225, At-211 and Pb-212, using IONETIX’s proprietary cyclotron accelerator technology. The company completed the installation and commissioning of the first cyclotron at the facility last year. A second cyclotron will be installed and commissioned in early 2025, adding both scalable supply capacity and onsite production redundancy. A second site at another US location is planned for 2026.<\/p>\n

“Commercial cyclotron-produced Ac-225 is a first, and a pivotal milestone for our alpha isotope program and the radiotherapeutic industry,” said David Eve<\/span>, VP of Medical Affairs at IONETIX. “The demand for alpha emitters is surging and this will allow researchers and drug developers to access these crucial isotopes to support their drug development work.”<\/p>\n

Utilizing cyclotrons to produce Ac-225 is a very clean and efficient production pathway that can safely scale with the appropriate target technology and infrastructure. “Our facility was purpose-built to produce alpha isotopes,” said Mark Leuschner<\/span>, PhD, VP of Nuclear and Radiation Sciences at IONETIX. “We have spent years diligently working through every detail of the production cycle to enable high-output, scaled production of Ac-225. We now have produced non-carrier added Ac-225 and have successfully demonstrated the performance and purity of our production platform.”<\/p>\n

“This marks a significant advancement towards establishing a secure and robust commercial-stage supply chain for Ac-225,” said Eve. “We look forward to building upon this success and scaling up production of Ac-225 to support the ultimate launch of these promising new cancer therapies.”<\/p>\n

IONETIX plans to release GMP grade Ac-225 to customers in late 2024.\u00a0\u00a0<\/p>\n

About IONETIX
Utilizing its proprietary cyclotron technology platform, IONETIX\u00a0has developed innovative solutions that enable access to scarce radioisotopes used for both diagnostic and therapeutic radiopharmaceuticals. IONETIX offers both high-purity Actinium-225 (Ac-225) and Astatine-211 (At-211) for use in targeted alpha therapies.\u202f IONETIX also provides N-13, F-18 and Ga-68 for diagnostic imaging. Its distribution supply chain includes contract drug manufacturing and “white glove” distribution logistics, allowing global access to these imaging agents and targeted radiotherapies.\u202f<\/p>\n

Contact:\u00a0 David Eve<\/span> * deve@ionetix.com<\/a>\u00a0* 812-972-0673\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

LANSING, Mich.<\/span>, June 7, 2024<\/span> \/PRNewswire\/ — IONETIX, a leading cyclotron technology innovator, isotope producer, and radiopharmaceutical manufacturer, announced today the successful production of Actinium-225 (“Ac-225”) at its isotope manufacturing facility located in Lansing, Michigan<\/span>.<\/p>\n

This first-of-kind facility is dedicated exclusively to producing alpha-emitting isotopes, including Ac-225, At-211 and Pb-212, using IONETIX’s proprietary cyclotron accelerator technology. The company completed the installation and commissioning of the first cyclotron at the facility last year. A second cyclotron will be installed and commissioned in early 2025, adding both scalable supply capacity and onsite production redundancy. A second site at another US location is planned for 2026.<\/p>\n

“Commercial cyclotron-produced Ac-225 is a first, and a pivotal milestone for our alpha isotope program and the radiotherapeutic industry,” said David Eve<\/span>, VP of Medical Affairs at IONETIX. “The demand for alpha emitters is surging and this will allow researchers and drug developers to access these crucial isotopes to support their drug development work.”<\/p>\n

Utilizing cyclotrons to produce Ac-225 is a very clean and efficient production pathway that can safely scale with the appropriate target technology and infrastructure. “Our facility was purpose-built to produce alpha isotopes,” said Mark Leuschner<\/span>, PhD, VP of Nuclear and Radiation Sciences at IONETIX. “We have spent years diligently working through every detail of the production cycle to enable high-output, scaled production of Ac-225. We now have produced non-carrier added Ac-225 and have successfully demonstrated the performance and purity of our production platform.”<\/p>\n

“This marks a significant advancement towards establishing a secure and robust commercial-stage supply chain for Ac-225,” said Eve. “We look forward to building upon this success and scaling up production of Ac-225 to support the ultimate launch of these promising new cancer therapies.”<\/p>\n

IONETIX plans to release GMP grade Ac-225 to customers in late 2024.\u00a0\u00a0<\/p>\n

About IONETIX
Utilizing its proprietary cyclotron technology platform, IONETIX\u00a0has developed innovative solutions that enable access to scarce radioisotopes used for both diagnostic and therapeutic radiopharmaceuticals. IONETIX offers both high-purity Actinium-225 (Ac-225) and Astatine-211 (At-211) for use in targeted alpha therapies.\u202f IONETIX also provides N-13, F-18 and Ga-68 for diagnostic imaging. Its distribution supply chain includes contract drug manufacturing and “white glove” distribution logistics, allowing global access to these imaging agents and targeted radiotherapies.\u202f<\/p>\n

Contact:\u00a0 David Eve<\/span> * deve@ionetix.com<\/a>\u00a0* 812-972-0673\u00a0<\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-3893","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/3893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3893"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/3893\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}